Corporate Presentation: September 2021

Corporate Presentation

September 2021

NASDAQ: OTLK

outlooktherapeutics.com

Disclaimer

This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutics" or the "Company") based on management's current expectations, which are subject to known and unknown uncertainties and risks. Words such as "anticipated," "initiate," "expect," "intend," "plan," "believe," "seek," "estimate," "may," "will," and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, among others, statements about ONS-5010's potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, our expectations for ONS-5010 market exclusivity, the timing of BLA submission and commercial launch of ONS-5010,ONS-5010's ability to replace and address issues with off-label use of Avastin, other drug candidates in development, commercial drivers for ONS-5010 and its potential, the success of ongoing ONS-5010 trials for wet AMD and planned trials for ONS-5010 for DME and BRVO. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, the risks inherent in developing pharmaceutical product candidates, conducting successful clinical trials, and obtaining regulatory approvals, as well as our ability to raise additional equity and debt financing on favorable terms, among other risk factors. These risks are described in more detail under the caption "Risk Factors" in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission ("SEC"). Moreover, Outlook Therapeutics operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied.

Except as required by law, neither Outlook Therapeutics nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. This presentation contains trademarks, registered marks and trade names of Outlook Therapeutics and of other companies. All such trademarks, registered marks and trade names are the property of their respective holders.

2

Enhancing the Standard

of Care For Retinal Disorders

3

Investment Highlights

Positive Phase 3 Results Demonstrated with Lead Program, ONS-5010(bevacizumab-vikg)1, for Treatment of Wet AMD

U.S. FDA BLA submission targeted for calendar Q1 2022

Potential to be first U.S. FDA approved ophthalmic formulation of bevacizumab

Pre-commercialization activities underway to support potential launch

Targeting $13.1 Billion Global Ophthalmic Anti-VEGF Market2

1.	ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab	4
2.	Guidehouse Triangulation of Global Data, Market Scope and Investor Forecasts (2020)

Leadership Team: Global Ophthalmic Development and Commercial Launch Excellence

C. RUSSELL TRENARY III	LAWRENCE KENYON	JEFF EVANSON	TERRY DAGNON
President, CEO and Director	Chief Financial Officer and Director	Chief Commercial Officer	Chief Operating Officer

RANDY THURMAN	MARK HUMAYUN, MD, PhD
Executive Chairman of the Board	Medical Advisor

5